Uncovering Scaling Laws to Infer Multidrug Response of Resistant Microbes and Cancer Cells

Cell Reports

Volumn 6, Issue 6, 2014, Pages 1073-1084

  Wood, Kevin B ^a   Wood, Kris C ^b,c   Nishida, Satoshi ^a   Cluzel, Philippe ^a  

^a HARVARD UNIVERSITY   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; LINEZOLID; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CHLORAMPHENICOL; LINCOMYCIN; NORFLOXACIN; TANESPIMYCIN; TRIMETHOPRIM;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CANCER STEM CELL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG LEGISLATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG SPECIFICITY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; EUKARYOTE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MELANOMA; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROKARYOTE; SACCHAROMYCES CEREVISIAE; SCALE UP; STAPHYLOCOCCUS AUREUS; TOXICITY AND INTOXICATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS FAECALIS; BACTERIAL INFECTIONS; DRUG EFFECTS; DRUG RESISTANCE; MICROBIOLOGY; MYCOSES; NEOPLASMS; PATHOLOGY; ALLOMETRY; BACTERIAL GROWTH; CELL PROLIFERATION; CHEMOTAXIS; DRUG ANTAGONISM; DRUG POTENCY; EPISTASIS; EUKARYOTIC CELL; GENE EXPRESSION; NON SMALL CELL LUNG CANCER; PHENOTYPIC VARIATION; PROBLEM SOLVING; PROKARYOTIC CELL; RESPONSE SURFACE METHOD; SCALING LAW; UPREGULATION;

BACTERIA (MICROORGANISMS);

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MYCOSES; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84897034626     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.02.007     Document Type: Article

References (36)

1. Balaban N.Q., Merrin J., Chait R., Kowalik L., Leibler S. Bacterial persistence as a phenotypic switch. Science 2004, 305:1622-1625.
2. Bliss C.I. The calculation of microbial assays. Bacteriol. Rev. 1956, 20:243-258.
3. Bollenbach T., Kishony R. Resolution of gene regulatory conflicts caused by combinations of antibiotics. Mol. Cell 2011, 42:413-425.
4. Bollenbach T., Quan S., Chait R., Kishony R. Nonoptimal microbial response to antibiotics underlies suppressive drug interactions. Cell 2009, 139:707-718.
5. Chait R., Craney A., Kishony R. Antibiotic interactions that select against resistance. Nature 2007, 446:668-671.
6. Cohen S.P., McMurry L.M., Hooper D.C., Wolfson J.S., Levy S.B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob. Agents Chemother. 1989, 33:1318-1325.
7. Dick J.E. Looking ahead in cancer stem cell research. Nat. Biotechnol. 2009, 27:44-46.
8. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
9. Feinerman O., Veiga J., Dorfman J.R., Germain R.N., Altan-Bonnet G. Variability and robustness in Tcell activation from regulated heterogeneity in protein levels. Science 2008, 321:1081-1084.
10. Fitzgerald J.B., Schoeberl B., Nielsen U.B., Sorger P.K. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2006, 2:458-466.
11. Garrett J.T., Arteaga C.L. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol. Ther. 2011, 11:793-800.
12. Glickman M.S., Sawyers C.L. Converting cancer therapies into cures: lessons from infectious diseases. Cell 2012, 148:1089-1098.
13. Greco W.R., Bravo G., Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 1995, 47:331-385.
14. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
15. Jeong H., Tombor B., Albert R., Oltvai Z.N., Barabási A.L. The large-scale organization of metabolic networks. Nature 2000, 407:651-654.
16. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., Emery C.M., Stransky N., Cogdill A.P., Barretina J., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
17. Keith C.T., Borisy A.A., Stockwell B.R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 2005, 4:71-78.
18. Korolev K.S., Müller M.J., Karahan N., Murray A.W., Hallatschek O., Nelson D.R. Selective sweeps in growing microbial colonies. Phys. Biol. 2012, 9:026008.
19. Lehár J., Zimmermann G.R., Krueger A.S., Molnar R.A., Ledell J.T., Heilbut A.M., Short G.F., Giusti L.C., Nolan G.P., Magid O.A., et al. Chemical combination effects predict connectivity in biological systems. Mol. Syst. Biol. 2007, 3:80.
20. Lehár J., Stockwell B.R., Giaever G., Nislow C. Combination chemical genetics. Nat. Chem. Biol. 2008, 4:674-681.
21. Levy S.B., Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 2004, 10(12, Suppl):S122-S129.
22. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953, 3:285-290.
23. Montagut C., Sharma S.V., Shioda T., McDermott U., Ulman M., Ulkus L.E., Dias-Santagata D., Stubbs H., Lee D.Y., Singh A., et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008, 68:4853-4861.
24. Palmer K.L., Daniel A., Hardy C., Silverman J., Gilmore M.S. Genetic basis for daptomycin resistance in enterococci. Antimicrob. Agents Chemother. 2011, 55:3345-3356.
25. Park H., Pontius W., Guet C.C., Marko J.F., Emonet T., Cluzel P. Interdependence of behavioural variability and response to small stimuli in bacteria. Nature 2010, 468:819-823.
26. Poulikakos P.I., Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011, 19:11-15.
27. Rand K.H., Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J.Antimicrob. Chemother. 2004, 53:530-532.
28. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
29. Sachlos E., Risueño R.M., Laronde S., Shapovalova Z., Lee J.H., Russell J., Malig M., McNicol J.D., Fiebig-Comyn A., Graham M., et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012, 149:1284-1297.
30. Scott M., Gunderson C.W., Mateescu E.M., Zhang Z., Hwa T. Interdependence of cell growth and gene expression: origins and consequences. Science 2010, 330:1099-1102.
31. Shoval O., Sheftel H., Shinar G., Hart Y., Ramote O., Mayo A., Dekel E., Kavanagh K., Alon U. Evolutionary trade-offs, Pareto optimality, and the geometry of phenotype space. Science 2012, 336:1157-1160.
32. Velenich A., Gore J. The strength of genetic interactions scales weakly with mutational effects. Genome Biol. 2013, 14:R76.
33. Wood K.B., Cluzel P. Trade-offs between drug toxicity and benefit in the multi-antibiotic resistance system underlie optimal growth of E. coli. BMC Syst. Biol. 2012, 6:48.
34. Wood K.C., Konieczkowski D.J., Johannessen C.M., Boehm J.S., Tamayo P., Botvinnik O.B., Mesirov J.P., Hahn W.C., Root D.E., Garraway L.A., Sabatini D.M. MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Sci. Signal. 2012, 5:rs4.
35. Xu L., Kikuchi E., Xu C., Ebi H., Ercan D., Cheng K.A., Padera R., Engelman J.A., Jänne P.A., Shapiro G.I., et al. Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res. 2012, 72:3302-3311.
36. Yeh P., Tschumi A.I., Kishony R. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 2006, 38:489-494.